Neoadjuvant Immunochemotherapy in Locally Advanced Esophagogastric Junction Adenocarcinoma
Status:
Not yet recruiting
Trial end date:
2029-01-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to access the safety and efficacy of neoadjuvant Immunotherapy
(Sintilimab, PD-1 inhibitor) combined with chemotherapy (Tegafur+Oxaliplatin) for locally
advanced esophagogastric junction adenocarcinoma.